{"id":"NCT01710709","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder","officialTitle":"A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2016-11","completion":"2016-12","firstPosted":"2012-10-19","resultsPosted":"2018-08-08","lastUpdate":"2018-09-21"},"enrollment":748,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":[]}],"arms":[{"label":"Experimental","type":"EXPERIMENTAL"}],"summary":"This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder. The trial will enroll subjects who completed Trial 31-08-250 and de novo subjects not participating in Trial 31-08-250.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Up to Week 52","effectByArm":[{"arm":"Phase C: Open-label IM Depot Maintenance Phase","deltaMin":374,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":142,"countries":["United States","Canada","France","Hungary","Japan","Malaysia","Poland","Romania","South Korea","Taiwan"]},"refs":{"pmids":["29886522"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":464},"commonTop":["Akathisia","Weight increased","Nasopharyngitis","Insomnia","Anxiety"]}}